88 123

Cited 0 times in

Anthracycline 의 치료력이 있는 전이성 유방암에 대한 Docetaxel 의 제 2 상 다기관 임상시험

Other Titles
 The Efficacy and Safety of Docetaxel in Patients with Anthracychne - pretreated Metastatic Breast Cancer : A Multicenter Phase II Study 
Authors
 안중배  ;  심광용  ;  박준오  ;  정희철  ;  유내춘  ;  정현철  ;  김주항  ;  최진혁  ;  김현수  ;  김효철  ;  김우건  ;  노재경 
Citation
 Journal of the Korean Cancer Association (대한암학회지), Vol.32(2) : 235-243, 2000 
Journal Title
Journal of the Korean Cancer Association(대한암학회지)
ISSN
 0496-6872 
Issue Date
2000
Keywords
Docetaxel ; Anthracycline ; Breast neoplasm ; Metastasis
Abstract
PURPOSE: Tbis phase II study was performed to evaluate the efficacy and safety of docetaxel0ain patients with anthracycline-pretreated metastatic breast cancer (MBC).0aMATERIALS AND METHODS: From September 1996 to January 1998, 27 patients with metastatic0abreast cancer from 31 to 63 years of age with a performance status of 0 to 2 were registered0ain the phase II trial. All patients had metastatic breast cancer which had progressed or0arelapsed 2 during or after treatment with an anthracycline-based regimen. Docetaxel 75 mg/m20awas ad- ministered over 1 hour every 21 days until disease progression was documented or0auntil toxic effects precluded further therapy. All patients received dexamethasone orally0aat the dose of 16 mg on days -1, 0, 1 of each cycle. 0aRESULTS: Objective responses were seen in 9 of 25 assessable patients (two complete and seven0apartial responses), with an overall objective response rale of 36%. The median duration of0aresponse was 36 weeks (range 19.0~40.5). The median time to progression and survival duration0awere 17.5 and 69 weeks, respectively, for assessable patients. One hundred fifty cycles0a(median, five) of docetaxel were administered. Among 27 patients assessable for toxicity,0athe following side effects were reported: nadir neutropenia grade 3 (4 patients) and0agrade 4 (22 patients); grade 2 stomatitis (6 patients); grade 2 alopecia (5 patients);0agrade 2 to 3 neurosensory toxicity (4 patients); no hypersensitivity reaction; mild fluid0aretention (4 patients). 0aCONCLUSION: Docetaxel is an active agent in patients with antracycline-pretreated metastatic0abreast cancer. Docetaxel was associated with severe but reversible neutropenia. Dexamethasone0aprevented hypersensitivity reactions and appeared to ameliorate fluid retention.
Files in This Item:
T200003366.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Joo Hang(김주항)
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/172255
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links